KEYNOTE - From Mitochondrial Discovery to Approved Therapy: Lessons for the Future of Medicine

We are pleased to announce that Dr. Hazel H. Szeto from Weill Medical College of Cornell University, USA, Confirmed as Keynote Speaker at Targeting Mitochondria 2026.
Pioneer of the First FDA-Approved Mitochondria-Targeted Therapy to Join Berlin Congress.

The World Mitochondria Society is honored to announce that Hazel H. Szeto has accepted our invitation to join Targeting Mitochondria 2026, which will take place in Berlin from October 21–23, 2026.

Dr. Szeto is internationally recognized for her groundbreaking work in mitochondria-targeted therapeutics and for helping transform mitochondrial science into real therapeutic progress. Her pioneering research led to one of the first FDA-approved mitochondria-targeted medicines, marking a historic milestone for the field.

At a time when mitochondrial medicine is moving from concept to clinical reality, her presence at Targeting Mitochondria 2026 represents a major moment for the global scientific community.

She will deliver a keynote lecture entitled: 
From Mitochondrial Discovery to Approved Therapy: Lessons for the Future of Medicine

Dr. Szeto will also participate in a high-level strategic discussion with selected speakers focused on a critical question for the future of the field:

How Do We Build the Next Successful Mitochondrial Drug?

This special session will explore the scientific, translational, regulatory, and clinical barriers that must be overcome to accelerate the next generation of mitochondrial therapies.

With the participation of Hazel H. Szeto, Targeting Mitochondria 2026 further strengthens its mission to connect frontier science with real-world medical innovation.

Berlin will host the next chapter of mitochondrial medicine.

For more information - 

Read the news on LinkedIn